Alex Shih-Min Huang

Alex Shih-Min Huang is a seasoned expert in oncology and translational medicine with extensive experience in developing and implementing biomarker strategies across multiple therapeutic modalities. Currently serving as Vice President and Head of Cell Therapy at BeiGene since April 2021, Alex has established a competitive research strategy for iPSC-derived CAR-T and TCR-T cell therapies. Prior roles include Senior Director at AbbVie, overseeing clinical biomarkers and translational research in oncology, and leadership positions at Pharmacyclics and Bristol-Myers Squibb, managing various teams in immuno-oncology. Earlier experience at Genentech and Sanofi focused on drug discovery and development, while foundational work at Novartis involved target identification and validation in signaling pathways. Alex holds a PhD in Microbiology and Immunology from the University of Rochester School of Medicine and Dentistry.